MI-MMS-HOLDINGS

MMS, a data-focused clinical research organization (CRO), announced today that Ben Dudley has been appointed as the company’s new Chief Commercial Officer (CCO). Based in the UK, Ben Dudley brings more than 25 years of life sciences expertise on the CRO and Sponsor side, holding previous operational and commercial leadership roles at Parexel, Covance, and AstraZeneca.

As CCO at MMS, Ben will focus on:

• Strategic growth planning, working closely with other members of the Executive Leadership Team (ELT) to refine the vision, strategy, and goals for continued growth and expansion of MMS globally.
• Commercial leadership, understanding sponsor needs and guiding customer relationship management across global accounts; and
• Marketing strategy, overseeing campaigns that showcase the value-add of MMS service offerings, which will impact our customer successes as well as have a positive impact on patient health.

“We were deliberate in our choice of a CCO who brings scientific strength, agility, and leadership to help continue to move MMS forward, and Ben’s experience is a great fit,” said Dr. Uma Sharma, CEO of MMS. “Ben’s passion for our industry, his commercial expertise, and proven leadership give us added momentum to drive our strategic vision, foster key partnerships, and significantly enhance our market presence.”

Data excellence is the need of the hour and what MMS brings to the industry.

"I am thrilled to join MMS at such an exciting time in the company's evolution," said Ben Dudley. "The company holds a significant place in the global CRO landscape, and I have witnessed the strength of their expertise over the years. I relish the opportunity to be part of the leadership of an organization with unique capabilities and culture as we continue the next stage of growth and delivery for our customers.”

This year, MMS celebrates 18 years globally, recently being named a Great Place to Work in all major regions of the world. MMS is known globally for data-focused CRO services, including:

• Bundled Biometrics solutions, starting with the IND, effectively managing all data collection, analysis, and integrating non-traditional data and submission analyses.
• Regulatory submissions, beginning with global regulatory strategy for multiple markets followed by execution of successful marketing applications (data, writing, and publishing/submission) with a flawless track record and industry leadership with over 50 submissions completed in the past five years.
• Other key areas, including Regulatory and Medical Writing from IND to Phase 3, Quality and Compliance (complete GxP globally), Drug Safety and Pharmacovigilance, Clinical Trial Transparency, and more.

View the entire MMS Executive Leadership Team (ELT) at https://www.mmsholdings.com/executive-leadership/

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717384423/en/